SCHEMBL2544089

SCHEMBL2544089

O=C1NC(=O)C(=Cc2cc(C(F)(F)F)ccc2F)S1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 3/20 0.67
▸ PIM2 Q9P1W9 3/20 0.67
▸ TTR P02766 1/20 0.61
▸ CISD1 Q9NZ45 1/20 0.61
▸ IGF1R P08069 2/20 0.61
▸ NR1H4 Q96RI1 1/20 0.57
▸ PTPN1 P18031 9/20 0.57
▸ RXRA P19793 1/20 0.51
▸ LMNA P02545 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ PTPN2 P17706 1/20 0.50
▸ PTPN6 P29350 1/20 0.50
▸ PPARG P37231 1/20 0.50
▸ ESRRA P11474 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2544087 1.00 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL2541255 0.89 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL2541256 0.89 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL13499580 0.86 CISD1 (0.63) PIM1PIM2CISD1
SCHEMBL2546073 0.86 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL2546075 0.86 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL2546069 0.83 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL2546068 0.83 PIM1 (0.67) PIM1PIM2TTRCISD1IGF1R
SCHEMBL2544047 0.81 PIM1 (1.00) PIM1PIM2TTRCISD1NR1H4
SCHEMBL2544050 0.81 PIM1 (1.00) PIM1PIM2TTRCISD1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 — — US claimed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 — — EP claimed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 — — WO claimed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 — — WO claimed
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2011-10-27 — — US disclosed
EP-2217235-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER Musc Foundation for Research Development (US) 2010-08-18 — — EP disclosed
WO-2009064486-A9 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2009-07-16 — — WO disclosed
WO-2009064486-A2 INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2009-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263664-A1 Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885TTR 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback